|Year : 2022 | Volume
| Issue : 4 | Page : 120-126
Effect of magnesium on severity and mortality of COVID–19 patients: A systematic review
Razieh Avan1, Afrooz Mazidimoradi2, Hamid Salehiniya3
1 Department of Clinical Pharmacy, School of Pharmacy, Medical Toxicology and Drug Abuse Research Center, Birjand University of Medical Sciences, Birjand, Iran
2 Shiraz University of Medical Sciences, Shiraz, Iran
3 Social Determinants of Health Research Center, Birjand University of Medical Sciences, Birjand, Iran
|Date of Submission||13-Jun-2022|
|Date of Decision||18-Jul-2022|
|Date of Acceptance||15-Aug-2022|
|Date of Web Publication||06-Sep-2022|
Social Determinants of Health Research Center, Birjand University of Medical Sciences, Birjand, Iran
Source of Support: This study received no extramural funding, Conflict of Interest: None
Unbalanced magnesium levels in the body, like other minerals, are a factor that is important in the severity and mortality of COVID-19. This study was designed to investigate the relationship between serum magnesium levels and clinical outcomes in COVID-19 patients. In this systematic review, a comprehensive search was performed in PubMed, Scopus, and Web of Science databases until September 2021 by using the keywords COVID-19, severe acute respiratory syndrome coronavirus 2, coronavirus disease, SARS- COV-infection 2, SARS-COV-2, COVID 19, and magnesium. End-Note X7 software was used to manage the studies. Articles that evaluated effect of magnesium on COVID-19 were included in the analysis. After reviewing several articles,12 studies were finally included in the ultimate analysis. The studies show that hypomagnesemia and hypermagnesemia are both factors that increase mortality in patients with COVID-19, even in one study, hypomagnesemia is the cause of doubling thedeaths in COVID-19 patients. Some studies have also found a negative correlation between magnesium deficiency and infectionseverity, while some others have reported no correlation between magnesium level and disease severity. According to the important role of magnesium in the body and its involvement in many physiological reactions, as well as differences in physical and physiological conditions of COVID-19 patients, in addition to the need for studies with larger sample sizes, monitoring and maintaining normal serum magnesium levels during the disease seems necessary as a therapeutic target, especially in patients admitted to the intensive care unit.
Keywords: Magnesium; Severity; Mortality; COVID-19; Systematic review
|How to cite this article:|
Avan R, Mazidimoradi A, Salehiniya H. Effect of magnesium on severity and mortality of COVID–19 patients: A systematic review. J Acute Dis 2022;11:120-6
|How to cite this URL:|
Avan R, Mazidimoradi A, Salehiniya H. Effect of magnesium on severity and mortality of COVID–19 patients: A systematic review. J Acute Dis [serial online] 2022 [cited 2022 Oct 3];11:120-6. Available from: https://www.jadweb.org/text.asp?2022/11/4/120/355308
| 1. Introduction|| |
The coronavirus is part of a viral family that is common in animals around the world, and few of them affect humans. In the last two decades, only two species (SARS and MERS) have caused two large-scale epidemics. However, a series of viralpneumonia cases with symptoms including fever, shortness of breath, cough, fatigue, and pneumonia have been reported. The disease was named by the World Health Organization coronavirus 2019 (COVID-19) and was finally declared a public health and pandemic challenge on March 11, 2020, due to its widespread in most countries and up to the 15th of August 2022, there were 587 396 589 definitive cases and 6428 661 mortalities.
Simultaneously with the onset of the pandemic, various researches were initiated to identify differential diagnostic methods and effective treatments of the disease. Magnesium was also studied as the fourth mineral element in the human bodythat reduces the severity of infectious and inflammatory diseases of the lungs and strengthens the immune system, which could be considered a treatment method in patients with COVID-19.
In the human body, magnesium has a cofactor role in more than 300 enzyme systems, that regulate various biochemical reactions. Normal magnesium concentrations range from 0.75 to 0.95 mmol/L and serum levels less than 1.7-1.8 mg/dL (0.75 mmol/L) are defined as hypomagnesaemia. Association of low magnesium levels with several chronic and inflammatory diseases such as Alzheimer’s disease, asthma, attention deficit hyperactivity disorder, insulin resistance, type 2 diabetes, hypertension, cardiovascular disease (such as stroke), migraine headaches, and osteoporosis have been confirmed. The relationship between the severity and mortality of COVID-19 and serum magnesium levels has been reported in studies to be different so that both magnesium deficiency and increased magnesium level are considered effective in the disease severity and mortality. Due to the limitations of published studies in this field, a comprehensive study is necessary for better decision-making by clinical specialists. Therefore, the present study investigated the relevance between the severity and mortality of COVID-19 and serum magnesium levels.
| 2. Methods|| |
2.1. Search strategy
This systematic review was conducted following the PRISMA Checklist. A comprehensive search was performed in three databases including PubMed/MEDLINE, Scopus, and Web of Science, using the following keywords COVID-19, COVID 19 pandemic, coronavirus disease 2019, SARS-CoV-2, COVID-19 virus infections, SARS coronavirus 2 infection, COVID 19, and magnesium from 2020 to September 2021. AND, OR, and Mesh term operators were also used to improve the search result.
2.2. Inclusion and exclusion criteria
Included articles in this review were all observational and interventional studies that investigated the impact of magnesium on COVID-19 and were published in the English language. Excluded articles were review studies, case reports, letters to editors, commentaries, and reports.
2.3. Study selection and data collection
All extract articles were entered into Endnote X7 software to remove duplicates. The remained studies were selected according to title and abstract, respectively. Then, their full text was reviewed for eligibility. Articles that investigated the effect of magnesium on COVID-19 were included in the analysis.
The prepared checklist was used to extract the data and information such as surname of the first author, year of publication, country of study, type of study, sample size, and the main findings extracted from each study.
2.4. Quality assessment
“Adapted Newcastle-Ottawa Quality Assessment Scales” checklist was used to assess the quality of the articles in this review. This tool consists of three separate parts: selection, comparison, and conclusion. Studies were scored based on overall scores and divided into 3 categories: good, moderate, and poor.
2.5. Data analysis
According to the goals of this study, included articles were divided into 8 groups: magnesium and mortality in COVID-19,,12], magnesium and hypokalemia in COVID-19, magnesium and markers of disease severity in COVID-19,,,,,, magnesium and need for mechanical ventilation in COVID-19, magnesium and need for vasopressors in COVID-19, magnesium and acute kidney injury (AKI) in COVID-19, magnesium and stay in Intensive Care Unit (ICU) in COVID-19 and level of magnesium in COVID-19 patients,,,,,,,,.
| 3. Results|| |
From 408 articles that were retrieved as the search result in the databases based on the intended keywords, after deleting duplicates (131 articles) and non-related articles according to the title and abstract (261 articles), 16 articles remained. Then, by a review of the remaining articles, 3 other articles were excluded due to combined intervention (1 article), a letter to the editor (1 article), and a conference paper (1 article). Afterward, the full text of the articles reviewed, 1 article was deleted due to lack of access to the full text, and finally, 12 articles remained for analysis in this systematic review [Figure 1].
Based on the result of quality assessment checklist, 9 articles were of good quality and three articles were of moderate quality. [Table 1] shows the summarized results.
3.1. Magnesium and mortality in COVID-19
In one retrospective study in Iran, the prognostic factors associated with mortality in patients with COVID-19 were investigated. The results showed that increased odds of in-hospital mortality were associated with decreased level of magnesium (OR=0.032, P<0.001) on admission. In another retrospective study in COVID-19 hospitalized patients in Iran, magnesium serum level with an average rank of 46.83 was one of the least important predictors of mortality in COVID-19 patients. A retrospective study in hospitalized COVID-19 patients in New York found an association between hypomagnesemia (>2.4 mg/dL) and increased mortality. This study showed that hypomagnesemia patients had twice mortality rate compared with patients with normal serum magnesium levels.
3.2. Magnesium and hypokalemia in COVID-19
In a retrospective study performed on non-ICU admitted COVID-19 patients in Modena, the serum magnesium level was not a predictive factor of hypokalemia (P=0.05).
3.3. Magnesium and markers of disease severity in COVID-19
In one study in Ankara, the magnesium level of pregnant women in the first trimester, was associated with white blood cell (P<0.001, r= −0.435), neutrophil (P=0.002, r= -0.366), lymphocyte (P=0.002, r= -0.378), erythrocyte sedimentation rate (P=0.001, r=0.384), hematocrit (P=0.02, r= -0.276) and creatinine (P=0.04, r= -0.250). In the third trimester, magnesium level was associated with lymphocyte (P=0.04, r= -0.254), C-reactive protein (P=0.03, r=0.271), ferritin (P=0.03, r= -0.272) and creatinine (P=0.01, r=0.306) levels. These results showed no correlation between disease severity and magnesium level. A cross-sectional study on ICU-admitted COVID-19 patients in Iran revealed an independent and inverse correlation between magnesium levels with a higher score of severity. The lower level of magnesium was significantly and independently correlated with higher APACHE scores and higher lung damage (P=0.028 and P=0.045, respectively). One study in pediatric COVID-1 9 patients in Iran revealed that magnesium can be considered a predictor of SARS-CoV-2 RNAaemia with an AUC level of 0.808. This study revealed that most of the patients with SARS-CoV-2 RNAaemia (67%) had a severe form of COVID-19 and one-third of these patients died. In a prospective cohort study in hospitalized patients with COVID-19 in France, there was a significant and negative association between magnesium deficiency and infection severity (P<0.001). After exclusion of sex ratio, the infection severity (OR=0.46, P=0.04, and OR=0.39, P=0.01) was the strongest predictor of magnesium deficiency for critical and moderate COVID-19, respectively. Also, the number of hypomagnesemia cases (<0.75 mmol/L) was significantly more in moderate COVID-19 patients than in critical form (P<0.001), while hypomagnesemia (≥0.95 mmol/L) was significantly increased in severity (P=0.040). In a cohort study in COVID-19 patients, magnesium levels did not correlate with SpO2, fever, lung involvement, CT grade, or C-reactive protein levels. In a cohort of COVID-19 patients in China, severe cases revealed significantly lower whole blood levels of magnesium compared with non-severe cases (P=0.002). However, the plasma magnesium level didn’t show a difference between the two groups (P=0.068). The hemoglobin and red blood cell were positively correlated with magnesium (CC=0.37 and 0.33).
3.4. Magnesium and need for mechanical ventilation in COVID-19
A retrospective study in hospitalized patients with COVID-19 in New York found that hypomagnesemia patients had more respiratory failure needing mechanical ventilation compared with normal magnesium level patients (28% vs. 21%, P=0.01).
3.5. Magnesium and need for vasopressors in COVID-19
One retrospective study in hospitalized COVID-19 patients in New York found that hypomagnesemia patients had more shock requiring pressors (35% vs. 27%, P<0.01).
3.6. Magnesium and acute kidney injury (AKI) in COVID-19
A retrospective study in patients hospitalized with COVID-19 in New York found that hypomagnesemia patients had more incidence of AKI (65% vs. 50%, P<0.001), and severe AKI to need renal replacement therapy (18% vs. 5%,P<0.001).
3.7. Magnesium and stay in ICU in COVID-19
In a prospective cohort study in hospitalized COVID-19 patients in France, there was a significant and negative association between magnesium deficiency and stay in ICU (P=0.028).
3.8. Level of magnesium in COVID-19 patients
In one study in Ankara, pregnant women with COVID-19 in the first and third trimesters had higher serum magnesium levels compared with healthy pregnant women, respectively [(1.557±0.211) mg/dL vs. (1.848±0.335) mg/dL, P<0.001 and (1.947±0.657) mg/dL vs. (2.767±0.394) mg/dL, P<0.001].
In a retrospective study performed on non-ICU admitted COVID-19 patients in Modena, magnesium level on admission was statistically significantly lower in hypokalemic compared with normokalaemic patients (P=0.028). A cross-sectional study on ICU-admitted COVID-19 patients in Iran reported low serum levels of magnesium in COVID-19 patients.
One study in pediatric COVID-19 patients in Iran showed that SARS-CoV-2 RNAanemia patients had a significantly lower level of magnesium. In a prospective cohort study in hospitalized COVID-19 patients in France, the serum magnesium level was statistically significantly lower in females compared with males [(0.73±0.12) mmol/L vs. (0.80±0.13) mmol/L)], while the sex ratio M/F was higher in severe and critical form of COVID-19 (P<0.001). Also, the risk of magnesium deficiency was significantly and negatively correlated with a sex ratio (M/F, P<0.001), oxygen therapy (P<0.001), and positive nephropathy (P=0.026). Also, female gender (OR=2.67, P<0.001) and nephropathy (OR=2.12, P=0.032) were the strongest predictors of magnesium deficiency.
In a cohort study in COVID-19 patients, no significant difference was seen in serum magnesium levels between patients and control groups. In a cross-sectional study performed in Iran in COVID-19 patients without underlying disease, the outpatient group had higher normal magnesium levels (1.8-2.2 mg/dL) compared with the ICU group. Also, hypomagnesemia (>2.6 mg/dL) in the ICU group was significantly higher compared to the outpatient group (P=0.04).
In the last laboratory test findings of inpatients with COVID-19 in China, the magnesium level was significantly increased in non-survivors in comparison to survivors (1.02 mmol/L vs. 0.90 mmol/L, P<0.001). A retrospective study in hospitalized COVID-19 patients in New York concluded that hypomagnesemia was seen more commonly with increases in age, male sex, AKI needing renal replacement therapy, hyperkalemia, and higher creatine phosphokinase.
| 4. Discussion|| |
This systematic review aimed to investigate changes in the severity and consequences of COVID-19 with serum magnesium levels and revealed that there is a relationship between severity of COVID-19, including the need for oxygen therapy, shock requiring pressors, stay in ICU and mortality and serum magnesium levels.
Magnesium is playing a role in a wide range of vital functions in human physiology. In addition to the immune system, magnesium is required for all enzymatic reactions requiring adenosine triphosphate and kinases, neuromuscular excitability, cell permeability, regulation of ion channels, mitochondrial function, cell proliferation, apoptosis, etc.
Hypomagnesemia is defined as Mg<1.7 mg/dL (0.7 mmol/L) in blood serum. Important signs and symptoms are seen when serum Mg is less than 1.2 mg/dL (0.5 mmol/L). Hypermagnesemia is identified as serum Mg greater than 2.6 mg/dL (1.1 mmol/L), which presented with important signs and symptoms when serum Mg is greater than 4.8 mg/dL or 2 mmol/L.
The results of multiple studies revealed that hypomagnesemia and hypermagnesemia both can increase the risk of mortality in patients with COVID-19. Although serum magnesium levels have been reported to be higher in patients who died of COVID-19, it does not affect predicting the prognosis of the disease.
Various studies have examined serum levels in patients with COVID-19. Numbers of studies have shown that patients with COVID-19 have low levels of magnesium,. However, a cohort study by Skalny et al. did not show the difference in magnesium levels in patients with COVID-19 and the control. Alfano et al. reported that magnesium serum levels at admission were significantly lower in hypokalemic patients than in normal patients, which is in line with the generally accepted logic that magnesium deficiency is often associated with hypokalemia. Magnesium deficiency simultaneously aggravates hypokalemia and makes it resistant to potassium therapy. Various investigations which revealed a relationship between serum magnesium levels and disease severity in patients with COVID-19 have reported different results. Some have found it to be ineflective,, some have linked magnesium deficiency to increased disease severity, and one study found a relationship between magnesium deficiency and moderate disease severity. While other investigations were reported severe hypomagnesemia and hypermagnesemia in COVID-19 patients which have severe disease and hospitalized in the ICU, some have reported that despite the same serum magnesium level in patients at admission, this value varies during the hospitalization period in patients with severe and moderate disease,. One study also found that hypermagnesemia was associated with an increased need for oxygen therapy and shock therapy, and increased the risk of renal failure in COVID-19 patients. While in a cohort study, Tan et al. showed that 150 mg of oral magnesium along with other supplements was effective in reducing the disease severity and the need for oxygen therapy and hospitalization in the ICU.
It is ambiguous how hypomagnesemia and hypermagnesemia affect the prognosis of COVID-19, only one study investigated thecause of hypomagnesemia in COVID-19 patients. This study reported that sex ratio, oxygen therapy, ICU admission period, andnephropathy were among the risk factors for hypomagnesemia in these patients, and female sex (OR=2.67,P<0.001) and nephropathy (OR=2.12, P=0.032) had the strongest association. However, there is growing evidence that magnesium deficiency causes a variety of diseases including the respiratory system, reproductive system, nervous system, gastrointestinal tract, and cardiovascular system disorders and nephropathy, diabetes, and cancer. On the other hand, Stevens et al. reported that hypermagnesemia in patients with increasing age, male gender, and acute nephropathy are more likely to have hyperkalemia and higher creatine phosphokinase and require renal replacement therapy. Also, because COVID-19, which is characterized by respiratory symptoms with varying degrees of damage to other organs and tissues, normal serum magnesium levels maintenance is important.
| 5. Conclusion|| |
According to the important role of magnesium in the body and its involvement in many physiological reactions, as well as differences in the physical and physiological conditions of patients, conducting studies with a small sample size would not be helpful for clinicians. However, according to these results, it can be concluded that the measurement of serum magnesium should be considered at the time of admission of patients. Also, if there are any side effects of reducing or increasing magnesium during treatment, the necessary monitoring during treatment to maintain magnesium at a normal level, especially in patients admitted to the ICU, should be considered.
Conflict of interest statement
The authors report no conflict of interest.
This study received no extramural funding.
H.S., R.A. and A.M. conceived of the presented idea and developed the theory and performed the computations. R.A. and A.M. verified the analytical methods. H.S. investigated and supervised the findings of this work. All authors discussed the results and contributed to the final manuscript.
| References|| |
Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty
Dhakal S, Karki S. Early epidemiological features of COVID-19 in Nepal and public health response. Front Med (Lausanne)
(524). DOI: 10.3389/fmed.2020.00524.
WHO. WHO Coronavirus (COVID-19) Dashboard. [Online] Available from: https://covid19.who.int/. [Accessed on August 15, 2022].
Al Alawi A, Majoni SW, Falhammar H. Magnesium and human health: perspectives and research directions. Int J Endocrinol
Gröber U, Schmidt J, Kisters K. Magnesium in prevention and therapy. Nutrients
Elin RJ. Assessment of magnesium status for diagnosis and therapy. Magnes Res 2010;23
Witkowski M, Hubert J, Mazur A. Methods of assessment of magnesium status in humans: a systematic review. Magnes Res
Fiorentini D, Cappadone C, Farruggia G, Prata C. Magnesium: biochemistry, nutrition, detection, and social impact of diseases linked to its deficiency. Nutrients
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [Online] Available from: https:// www.ohri.ca//programs/clinical_epidemiology/oxford.asp. [Accessed on October 11, 2021].
Alamdari NM, Afaghi S, Rahimi FS, Tarki FE, Tavana S, Zali A, et al. Mortality risk factors among hospitalized COVID-19 patients in a major referral center in Iran. Tohoku J Exp Med
Shanbehzadeh M, Orooji A, Kazemi-Arpanahi H. Comparing of data mining techniques for predicting in-hospital mortality among patients with COVID-19. J Biostat Epidemiol
Stevens JS, Moses AA, Nickolas TL, Husain SA, Mohan S. Increased mortality associated with hypermagnesemia in severe COVID-19 illness. Kidney 360
Alfano G, Ferrari A, Fontana F, Perrone R, Mori G, Ascione E, et al. Hypokalemia in patients with COVID-19. Clin Exp Nephrol
Anuk AT, Polat N, Akdas S, Erol SA, Tanacan A, Biriken D, et al. The relation between trace element status (zinc, copper, magnesium) and clinical outcomes in COVID-19 infection during pregnancy. Biol Trace Elem Res
Beigmohammadi MT, Bitarafan S, Abdollahi A, Amoozadeh L, Salahshour F, Mahmoodi Ali Abadi M, et al. The association between serum levels of micronutrients and the severity of disease in patients with COVID-19. Nutrition
Pourakbari B, Mahmoudi S, Mahmoudieh Y, Eshaghi H, Navaeian A, Rostamyan M, et al. SARS-CoV-2 RNAaemia in children: An Iranian referral hospital-based study. J Med Virol
Quilliot D, Bonsack O, Jaussaud R, Mazur A. Dysmagnesemia in Covid-19 cohort patients: Prevalence and associated factors. Magnes Res
Skalny AV, Timashev PS, Aschner M, Aaseth J, Chernova LN, Belyaev VE, et al. Serum zinc, copper, and other biometals are associated with COVID-19 severity markers. Metabolites
Zeng HL, Yang Q, Yuan P, Wang X, Cheng L. Associations of essential and toxic metals/metalloids in whole blood with both disease severity and mortality in patients with COVID-19. FASEB J
Sarvazad H, Cahngaripour SH, Eskandari Roozbahani N, Izadi B. Evaluation of electrolyte status of sodium, potassium and magnesium, and fasting blood sugar at the initial admission of individuals with COVID-19 without underlying disease in Golestan Hospital, Kermanshah. New Microbes New Infect
Ouyang SM, Zhu HQ, Xie YN, Zou ZS, Zuo HM, Rao YW, et al. Temporal changes in laboratory markers of survivors and non-survivors of adult inpatients with COVID-19. BMC Infect Dis
Pham PC, Pham PA, Pham SV, Pham PT, Pham PM, Pham PT. Hypomagnesemia: a clinical perspective. Int J Nephrol Renovasc Dis
2014; 7: 219-230.
Tinawi M. Disorders of magnesium metabolism: hypomagnesemia and hypermagnesemia. Arch Clin Biomed Res
Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol
Tan CW, Ho LP, Kalimuddin S, Cherng BPZ, Teh YE, Thien SY, et al. Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19). Nutrition
Tang CF, Ding H, Jiao RQ, Wu XX, Kong LD. Possibility of magnesium supplementation for supportive treatment in patients with COVID-19. Eur J Pharmacol